"Phenylpropionates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of 3-phenylpropionic acid, including its salts and esters.
Below are MeSH descriptors whose meaning is more general than "Phenylpropionates".
Below are MeSH descriptors whose meaning is more specific than "Phenylpropionates".
This graph shows the total number of publications written about "Phenylpropionates" by people in this website by year, and whether "Phenylpropionates" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Phenylpropionates" by people in Profiles.
A triple-blind randomized clinical trial of different associations between dexamethasone and non-steroids anti-inflammatories for preemptive action in third molar extractions. Sci Rep. 2021 12 27; 11(1):24445.
Treatment with TUG891, a free fatty acid receptor 4 agonist, restores adipose tissue metabolic dysfunction following chronic sleep fragmentation in mice. Int J Obes (Lond). 2016 07; 40(7):1143-9.
Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone. 2013 Sep; 56(1):154-62.
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
The ARABIDOPSIS accession Pna-10 is a naturally occurring sng1 deletion mutant. Mol Plant. 2010 Jan; 3(1):91-100.
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition? Curr Med Res Opin. 2006 Dec; 22(12):2567-74.
Activation tagging identifies a conserved MYB regulator of phenylpropanoid biosynthesis. Plant Cell. 2000 Dec; 12(12):2383-2394.